OrbusNeich, a Hong Kong-based firm that designs, develops, manufactures and markets medical devices for the treatment of vascular diseases, has launched Genous Bio-engineered Cobalt Chromium Stent into the market following the CE Mark (Conformite Europeenne) approval.
The Genous Bio-engineered Cobalt Chromium Stent combines OrbusNeich’s patented endothelial progenitor cell (EPC) capture technology Genous with a L605 cobalt chromium bare metal stent based on the company’s proven Blazer stent design.
OrbusNeich claimed that the thin cobalt chromium stent struts exhibit a low profile and great flexibility for ideal deliverability, while the dual helix stent design provides superior radial strength and excellent sidebranchability for effective bifurcation stenting.
The combination of the Genous technology with the new platform provides physicians with a stent designed to modulate restenosis and protect against thrombosis.
Smith, doctor in Morriston Hospital, Swansea, Wales, UK, said: “The cobalt chromium Genous stent will allow us to use its superior mechanical properties to provide further treatment options in tortuous, complex or distal coronary disease, especially in those patients in whom prolonged dual anti-platelet therapy is undesirable.”
Al Novak, chairman and CEO of OrbusNeich, said: “OrbusNeich is excited to offer the effective and proven EPC capture technology on a thin cobalt chromium stent. Interventional cardiologists now have more choices to treat challenging patient groups, such as diabetic patients, with a safe and effective alternative to drug-eluting stents.”